Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Revenue (2016 - 2025)

Amicus Therapeutics filings provide 14 years of Revenue readings, the most recent being $185.2 million for Q4 2025.

  • On a quarterly basis, Revenue rose 23.72% to $185.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $634.2 million, a 20.05% increase, with the full-year FY2025 number at $634.2 million, up 20.05% from a year prior.
  • Revenue hit $185.2 million in Q4 2025 for Amicus Therapeutics, up from $169.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $185.2 million in Q4 2025 to a low of $66.4 million in Q1 2021.
  • Median Revenue over the past 5 years was $99.0 million (2023), compared with a mean of $109.8 million.
  • Biggest five-year swings in Revenue: increased 2.7% in 2022 and later surged 36.73% in 2024.
  • Amicus Therapeutics' Revenue stood at $82.2 million in 2021, then grew by 7.23% to $88.1 million in 2022, then skyrocketed by 30.63% to $115.1 million in 2023, then surged by 30.09% to $149.7 million in 2024, then increased by 23.72% to $185.2 million in 2025.
  • The last three reported values for Revenue were $185.2 million (Q4 2025), $169.1 million (Q3 2025), and $154.7 million (Q2 2025) per Business Quant data.